NEW YORK, Aug. 12, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. “We are pleased to welcome both Dr. Bruhn and […]
Read MoreYou are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
